Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Future Oncol
; 17(22): 2883-2892, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-33858190
Lay abstract To assess the effectiveness of acute myeloid leukemia (AML) treatments, researchers use statistical models to estimate the survival rate of patients who receive a particular treatment. Some patients receiving certain AML treatments can achieve long-term remission and are often considered 'cured'. Standard statistical models cannot differentiate between cured and uncured patients and so tend to underestimate the survival rates of cured patients. Mixture cure models (MCMs) can account separately for the survival of cured versus uncured patients. We tested MCMs and standard statistical models using data from a clinical trial comparing gemtuzumab ozogamicin (GO) + standard chemotherapy against standard chemotherapy alone in AML patients. Of all the models tested, MCMs generated survival extrapolations over time that most closely resembled the data from the clinical trial. Through our analyses, we demonstrated that GO + standard chemotherapy can result in higher survival rates than standard chemotherapy alone.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Leucemia Mieloide Aguda
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Gemtuzumab
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article